A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity (APRICUS)
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Obesity or Overweight With Comorbidity
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index [BMI] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The study will comprise of:
A screening period of maximum 28 days
A treatment period of 36 weeks
A follow up period after last dose of study drug
This study will consist of 4 cohorts. Approximately 231 eligible participants will be randomized to AZD6234 or placebo
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Heidelberg, Australia, 3081
- Research Site
-
Maroochydore, Australia, 4556
- Research Site
-
Maroubra, Australia, 2035
- Research Site
-
Merewether, Australia, 2291
- Research Site
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 5G8
- Research Site
-
Sarnia, Ontario, Canada, N7T 4X3
- Research Site
-
Stouffville, Ontario, Canada, L4A1H2
- Research Site
-
Toronto, Ontario, Canada, M3J 0K2
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H4N 2W2
- Research Site
-
Sherbrooke, Quebec, Canada, J1L 0H8
- Research Site
-
-
-
-
-
Chūōku, Japan, 103-0027
- Research Site
-
Chūōku, Japan, 104-0031
- Research Site
-
Shinjuku-ku, Japan, 160-0008
- Research Site
-
Suita-shi, Japan, 565-0853
- Research Site
-
-
-
-
-
Hull, United Kingdom, HU3 2PA
- Research Site
-
Leicester, United Kingdom, Le5 4PW
- Research Site
-
Penarth, United Kingdom, CF64 2XX
- Research Site
-
Rotherham, United Kingdom, S65 1DA
- Research Site
-
-
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- Research Site
-
-
Arizona
-
Phoenix, Arizona, United States, 85044
- Research Site
-
-
California
-
Long Beach, California, United States, 90815
- Research Site
-
-
Florida
-
Hialeah, Florida, United States, 33012
- Research Site
-
Largo, Florida, United States, 33777
- Research Site
-
Orlando, Florida, United States, 32825
- Research Site
-
Tampa, Florida, United States, 33606
- Research Site
-
-
Georgia
-
Woodstock, Georgia, United States, 30189
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Research Site
-
-
Maryland
-
Lutherville-Timonium, Maryland, United States, 21093
- Research Site
-
-
Mississippi
-
Gulfport, Mississippi, United States, 39503
- Research Site
-
Ridgeland, Mississippi, United States, 39157
- Research Site
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68134
- Research Site
-
-
New Hampshire
-
Portsmouth, New Hampshire, United States, 03801
- Research Site
-
-
North Carolina
-
Statesville, North Carolina, United States, 28625
- Research Site
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29405
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37938
- Research Site
-
-
Texas
-
Austin, Texas, United States, 78731
- Research Site
-
Dallas, Texas, United States, 75230
- Research Site
-
Port Arthur, Texas, United States, 77642
- Research Site
-
San Antonio, Texas, United States, 78249
- Research Site
-
San Antonio, Texas, United States, 78231
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults ≥ 18 years of age
- BMI of (a) ≥ 30 kg/m2, or (b) ≥ 27kg/m2 and have a current diagnosis of at least 1 weight-related comorbidities (treated or untreated)
- A stable body weight for 3 months prior to Screening (±5% body weight change)
Exclusion Criteria:
- Have obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome
- Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening
- Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
- History of type 1 diabetes mellitus or T2DM
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1
Dose 1 |
IMP injected subcutaneously, once a week. Unit dose strength as per CSP |
|
Experimental: Arm 2
Dose 2 |
IMP injected subcutaneously, once a week. Unit dose strength as per CSP |
|
Experimental: Arm 3
Dose 3 |
IMP injected subcutaneously, once a week. Unit dose strength as per CSP |
|
Placebo Comparator: Arm 4
Placebo - Dose matched with each Experimental arm |
Placebo matching IMP dose injected subcutaneously, once a week. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent change in body weight from baseline to week 26
Time Frame: 26 weeks
|
To determine whether AZD6234 is superior to placebo for weight loss |
26 weeks
|
|
Weight loss ≥ 5% from baseline weight to week 26
Time Frame: 26 weeks
|
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 5% from baseline |
26 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight loss ≥ 5% from baseline to week 36
Time Frame: 36 weeks
|
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 5% from baseline |
36 weeks
|
|
Weight loss ≥ 10% from baseline to week 36
Time Frame: 36 weeks
|
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 10% from baseline |
36 weeks
|
|
Percent change in body weight from baseline to week 36
Time Frame: 36 weeks
|
To determine whether AZD6234 is superior to placebo for weight loss |
36 weeks
|
|
Absolute change in body weight (kg) from baseline to week 26 and week 36
Time Frame: week 26 and week 36
|
To determine whether AZD6234 is superior to placebo for absolute weight loss |
week 26 and week 36
|
|
AZD6234 plasma concentrations
Time Frame: Week 43
|
To characterise the PK of AZD6234 |
Week 43
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D8750C00004
- 2024-514000-13-00 (Registry Identifier: EU CT number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.